Biotech M&A Surges in Advance of Patent Expirations

[author: Michael Shuster]

We've known for some time that the pharma patent cliff was driving M&A, and now we have additional empirical evidence. Biotech M&A is at a 5 year high, according to Reuters. The volume of biotech M&A is more than $25 billion so far this year, with particular strength in oncology and immunology.

It serves as a good reminder to life science companies to have their patents in good shape and be up-to-date on the latest in confidentiality agreements for when suitors come knocking.


Written by:

Published In:

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Fenwick & West Life Sciences Group | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »

All the intelligence you need, in one easy email:

Great! Your first step to building an email digest of JD Supra authors and topics. Log in with LinkedIn so we can start sending your digest...

Sign up for your custom alerts now, using LinkedIn ›

* With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name.